Recent Phase 1b clinical study results concluded continuous low dose lenalidomide provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity PARAMUS, N.J ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback